JP2022506503A5 - - Google Patents

Info

Publication number
JP2022506503A5
JP2022506503A5 JP2021523902A JP2021523902A JP2022506503A5 JP 2022506503 A5 JP2022506503 A5 JP 2022506503A5 JP 2021523902 A JP2021523902 A JP 2021523902A JP 2021523902 A JP2021523902 A JP 2021523902A JP 2022506503 A5 JP2022506503 A5 JP 2022506503A5
Authority
JP
Japan
Prior art keywords
nucleotides
antisense strand
dsrna agent
sense strand
strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523902A
Other languages
English (en)
Japanese (ja)
Other versions
JP7536007B2 (ja
JP2022506503A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059818 external-priority patent/WO2020097044A1/en
Publication of JP2022506503A publication Critical patent/JP2022506503A/ja
Publication of JP2022506503A5 publication Critical patent/JP2022506503A5/ja
Priority to JP2024129696A priority Critical patent/JP2024149701A/ja
Application granted granted Critical
Publication of JP7536007B2 publication Critical patent/JP7536007B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523902A 2018-11-09 2019-11-05 修飾二重鎖オリゴヌクレオチド Active JP7536007B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024129696A JP2024149701A (ja) 2018-11-09 2024-08-06 修飾二重鎖オリゴヌクレオチド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862758094P 2018-11-09 2018-11-09
US62/758,094 2018-11-09
PCT/US2019/059818 WO2020097044A1 (en) 2018-11-09 2019-11-05 Modified double stranded oligonucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024129696A Division JP2024149701A (ja) 2018-11-09 2024-08-06 修飾二重鎖オリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2022506503A JP2022506503A (ja) 2022-01-17
JP2022506503A5 true JP2022506503A5 (cg-RX-API-DMAC7.html) 2022-09-20
JP7536007B2 JP7536007B2 (ja) 2024-08-19

Family

ID=70612465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523902A Active JP7536007B2 (ja) 2018-11-09 2019-11-05 修飾二重鎖オリゴヌクレオチド
JP2024129696A Pending JP2024149701A (ja) 2018-11-09 2024-08-06 修飾二重鎖オリゴヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024129696A Pending JP2024149701A (ja) 2018-11-09 2024-08-06 修飾二重鎖オリゴヌクレオチド

Country Status (6)

Country Link
US (1) US12600965B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877524A4 (cg-RX-API-DMAC7.html)
JP (2) JP7536007B2 (cg-RX-API-DMAC7.html)
AU (2) AU2019376628B2 (cg-RX-API-DMAC7.html)
CA (1) CA3118537A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020097044A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2970974T (pt) 2013-03-14 2017-11-29 Alnylam Pharmaceuticals Inc Composições de irna de componente do complemento c5 e métodos para a sua utilização
TWI851574B (zh) 2018-05-14 2024-08-11 美商阿尼拉製藥公司 血管收縮素原(AGT)iRNA組成物及其使用方法
US12600965B2 (en) * 2018-11-09 2026-04-14 Alnylam Pharmaceuticals, Inc. Modified double stranded oligonucleotide
IL292865A (en) * 2019-11-13 2022-07-01 Alnylam Pharmaceuticals Inc Methods and preparations for the treatment of angiotensinogen-related disorder - (agt)
CN116761616A (zh) * 2021-01-22 2023-09-15 阿耐拉姆制药公司 经修饰的双链寡核苷酸
EP4291654A2 (en) 2021-02-12 2023-12-20 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
BR112023019981A2 (pt) 2021-03-29 2023-12-12 Alnylam Pharmaceuticals Inc Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
KR20240067943A (ko) 2021-09-24 2024-05-17 알닐람 파마슈티칼스 인코포레이티드 미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
IL315546A (en) 2022-03-16 2024-11-01 Empirico Inc GALNAC compositions to improve siRNA bioavailability
EP4499834A2 (en) 2022-03-28 2025-02-05 Empirico Inc. Modified oligonucleotides
IL322261A (en) * 2023-02-09 2025-09-01 Alnylam Pharmaceuticals Inc Reverser molecules and methods of using them
WO2026046152A1 (zh) * 2024-08-26 2026-03-05 倍臻生物技术(苏州)有限公司 修饰的双链核糖核酸及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013117288A (ru) * 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
UA118649C2 (uk) 2011-11-18 2019-02-25 Елнілем Фармасьютікалз, Інк. ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
US9796974B2 (en) 2011-11-18 2017-10-24 Alnylam Pharmaceuticals, Inc. Modified RNAi agents
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
AU2014268529C1 (en) 2013-05-22 2020-10-01 Alnylam Pharmaceuticals, Inc. TMPRSS6 iRNA compositions and methods of use thereof
WO2015042564A1 (en) 2013-09-23 2015-03-26 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing transthyretin (ttr) associated diseases
WO2015051318A1 (en) 2013-10-04 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
IL316808A (en) * 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
TWI864340B (zh) 2014-10-10 2024-12-01 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
TWI769565B (zh) 2014-11-10 2022-07-01 美商阿尼拉製藥公司 B型肝炎病毒(HBV)iRNA組成物及其用途方法
WO2016081444A1 (en) * 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016085852A1 (en) 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
BR112017021053A2 (en) * 2015-04-13 2018-08-14 Alnylam Pharmaceuticals, Inc. angiopoietin type 3 (angpt13) irna compositions and methods of use thereof
US10494632B2 (en) * 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
LT3329002T (lt) 2015-07-31 2021-01-11 Alnylam Pharmaceuticals, Inc. Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
EP3340994A1 (en) 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
US11260134B2 (en) 2016-09-29 2022-03-01 National University Corporation Tokyo Medical And Dental University Double-stranded nucleic acid complex having overhang
TW202313978A (zh) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
WO2018098328A1 (en) 2016-11-23 2018-05-31 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
TWI865997B (zh) 2016-12-16 2024-12-11 美商阿尼拉製藥公司 使用甲狀腺素運載蛋白(TTR)iRNA組成物於治療或預防TTR相關疾病之方法
WO2018195165A1 (en) 2017-04-18 2018-10-25 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
CA3069868A1 (en) 2017-07-13 2019-01-17 Alnylam Pharmaceuticals Inc. Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2020036862A1 (en) 2018-08-13 2020-02-20 Alnylam Pharmaceuticals, Inc. HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
US12600965B2 (en) * 2018-11-09 2026-04-14 Alnylam Pharmaceuticals, Inc. Modified double stranded oligonucleotide

Similar Documents

Publication Publication Date Title
JP2008283975A5 (cg-RX-API-DMAC7.html)
JP2020188756A5 (cg-RX-API-DMAC7.html)
JP2005517452A5 (cg-RX-API-DMAC7.html)
JP2013535212A5 (cg-RX-API-DMAC7.html)
JP2006502694A5 (cg-RX-API-DMAC7.html)
JP2019141097A5 (cg-RX-API-DMAC7.html)
JP2005524393A5 (cg-RX-API-DMAC7.html)
JP2009060893A5 (cg-RX-API-DMAC7.html)
JP2018512041A5 (cg-RX-API-DMAC7.html)
JP2020500929A5 (cg-RX-API-DMAC7.html)
JP2005517430A5 (cg-RX-API-DMAC7.html)
JP2005517433A5 (cg-RX-API-DMAC7.html)
JP2005517432A5 (cg-RX-API-DMAC7.html)
HRP20210612T1 (hr) Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
JP2024105284A5 (cg-RX-API-DMAC7.html)
WO2015051366A3 (en) Novel formats for organic compounds for use in rna interference
JP2005517427A5 (cg-RX-API-DMAC7.html)
HRP20191232T1 (hr) Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
JP2003520811A5 (cg-RX-API-DMAC7.html)
JP2016116520A5 (cg-RX-API-DMAC7.html)
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
JP2022511550A5 (cg-RX-API-DMAC7.html)
WO2005014782A3 (en) Double-stranded ribonucleic acid with increased effectiveness in an organism
WO2004029212A3 (en) In vivo gene silencing by chemically modified and stable sirna
JP2013226147A5 (cg-RX-API-DMAC7.html)